CLGN CollPlant Biotechnologies Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLGN

Price (delayed)

$0.3813

Market cap

$5.5M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.03

Enterprise value

$3.89M

?
Relative Growth: Rel. Growth: 27
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 5

collplant is a regenerative medicine company focused on 3d bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. our ...

Highlights
The debt has contracted by 7% from the previous quarter and by 7% YoY
The company's EPS rose by 16% YoY but it fell by 10% QoQ
The company's net income fell by 14% QoQ but it rose by 5% YoY
CLGN's gross profit has plunged by 148% YoY and by 137% from the previous quarter
The revenue has plunged by 84% YoY and by 84% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.collplant.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CLGN

CLGN stock price

How has the CollPlant Biotechnologies stock price performed over time
Intraday
-4.65%
1 week
-5.85%
1 month
-8.78%
1 year
-82.67%
YTD
-72.76%
QTD
-28.86%

Financial performance

How have CollPlant Biotechnologies's revenue and profit performed over time
Revenue
$389,000
Gross profit
-$574,000
Operating income
-$12.95M
Net income
-$13.13M
Gross margin
-147.6%
Net margin
-3,376.3%
CLGN's gross profit has plunged by 148% YoY and by 137% from the previous quarter
The revenue has plunged by 84% YoY and by 84% from the previous quarter
The company's net income fell by 14% QoQ but it rose by 5% YoY
CollPlant Biotechnologies's operating income has decreased by 13% QoQ but it has increased by 11% YoY

Price vs fundamentals

How does CLGN's price correlate with its fundamentals

Growth

What is CollPlant Biotechnologies's growth rate over time

Valuation

What is CollPlant Biotechnologies stock price valuation
P/E
N/A
P/B
1
P/S
13.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.99
The company's EPS rose by 16% YoY but it fell by 10% QoQ
The P/B is 61% less than the 5-year quarterly average of 2.7 and 56% less than the last 4 quarters average of 2.4
The equity has plunged by 61% YoY and by 20% from the previous quarter
The revenue has plunged by 84% YoY and by 84% from the previous quarter
CLGN's price to sales (P/S) is 76% lower than its 5-year quarterly average of 59.3 but 17% higher than its last 4 quarters average of 12.1

Efficiency

How efficient is CollPlant Biotechnologies business performance
CollPlant Biotechnologies's ROE has plunged by 84% YoY and by 40% from the previous quarter
CLGN's ROA has dropped by 56% year-on-year and by 32% since the previous quarter
The ROIC has contracted by 22% from the previous quarter and by 20% YoY

Dividends

What is CLGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLGN.

Financial health

How did CollPlant Biotechnologies financials performed over time
CLGN's total assets is 114% greater than its total liabilities
The quick ratio has plunged by 56% YoY and by 16% from the previous quarter
The current ratio has declined by 49% year-on-year and by 10% since the previous quarter
The debt is 46% less than the equity
CollPlant Biotechnologies's debt to equity has surged by 135% YoY and by 15% QoQ
The equity has plunged by 61% YoY and by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.